Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Equities researchers at Leerink Swann dropped their FY2017 EPS estimates for Amicus Therapeutics in a research note issued on Wednesday. Leerink Swann analyst J. Schwartz now forecasts that the biopharmaceutical company will earn ($1.77) per share for the year, down from their previous estimate of ($1.31). Leerink Swann currently has a “Buy” rating and a $20.00 target price on the stock. Leerink Swann also issued estimates for Amicus Therapeutics’ Q4 2017 earnings at ($0.34) EPS, FY2018 earnings at ($1.24) EPS, FY2019 earnings at ($0.91) EPS and FY2020 earnings at ($0.71) EPS.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The business had revenue of $10.90 million for the quarter, compared to the consensus estimate of $9.02 million. During the same quarter last year, the business earned ($0.33) EPS. Amicus Therapeutics’s revenue for the quarter was up 419.0% compared to the same quarter last year.

WARNING: “Amicus Therapeutics, Inc. Expected to Earn FY2017 Earnings of ($1.77) Per Share (FOLD)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/14/amicus-therapeutics-inc-expected-to-earn-fy2017-earnings-of-1-77-per-share-fold.html.

Several other brokerages also recently weighed in on FOLD. Zacks Investment Research downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 12th. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $17.00 target price on shares of Amicus Therapeutics in a research note on Friday, October 6th. Chardan Capital reissued a “buy” rating and issued a $18.50 target price (up previously from $16.50) on shares of Amicus Therapeutics in a research note on Thursday, October 5th. Robert W. Baird reissued an “outperform” rating and issued a $18.00 target price (up previously from $16.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Finally, J P Morgan Chase & Co reissued an “overweight” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Amicus Therapeutics has a consensus rating of “Buy” and a consensus price target of $17.81.

Amicus Therapeutics (FOLD) opened at $13.00 on Monday. Amicus Therapeutics has a 12-month low of $4.41 and a 12-month high of $16.60. The company has a quick ratio of 6.22, a current ratio of 6.32 and a debt-to-equity ratio of 0.39.

In related news, CEO John F. Crowley sold 71,735 shares of the firm’s stock in a transaction dated Wednesday, October 18th. The shares were sold at an average price of $14.75, for a total value of $1,058,091.25. Following the transaction, the chief executive officer now owns 380,723 shares of the company’s stock, valued at approximately $5,615,664.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael Raab sold 10,000 shares of the firm’s stock in a transaction dated Thursday, October 12th. The stock was sold at an average price of $14.25, for a total transaction of $142,500.00. The disclosure for this sale can be found here. Insiders sold a total of 628,224 shares of company stock worth $9,024,003 in the last ninety days. 3.40% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of FOLD. Strs Ohio purchased a new position in Amicus Therapeutics during the 3rd quarter valued at about $102,000. Teacher Retirement System of Texas increased its position in Amicus Therapeutics by 1.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 169 shares during the period. DORCHESTER WEALTH MANAGEMENT Co purchased a new position in Amicus Therapeutics during the 2nd quarter valued at about $111,000. Tudor Investment Corp ET AL purchased a new position in Amicus Therapeutics during the 2nd quarter valued at about $124,000. Finally, Aperio Group LLC increased its position in Amicus Therapeutics by 13.5% during the 2nd quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 1,663 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Earnings History and Estimates for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.